Reference intervals of plasma matrix metalloproteinases 2, 3, and 9 and serum asymmetric dimethylarginine levels

References

• Liu P, Sun M, Sader S. Matrix metalloproteinases in cardiovascular disease. Can J Cardiol 2006;22:25B–30B.
   PubMed Web of Science ®Google Scholar
• Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562–73.
   PubMed Web of Science ®Google Scholar
• Böger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the “L-arginine paradox” and acts as a novel cardiovascular risk factor. J Nutr 2004;134:2842–7.
   PubMed Web of Science ®Google Scholar
• Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet 1992;339:572–5.
   PubMed Web of Science ®Google Scholar
• Böger RH, Bode-Böger SM, Szuba A, Tangphao O, Tsao PS, Chan JR, Blaschke TF, Cooke JP. ADMA: a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 1998;98:1842–7.
   PubMed Web of Science ®Google Scholar
• Solberg HE. International Federation of Clinical Chemistry (IFCC). Scientific Committee, Clinical Section. Expert Panel on Theory of Reference Values (EPTRV) and International Committee for Standardization in Haematology (ICSH), Standing Committee on Reference Values. Approved recommendation (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits. J Clin Chem Clin Biochem 1987;25:645–56. Clin Chim Acta 1987;170:S13–S32.
   Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline. CLSI document C28–A3. 3rd ed. Wayne: PA: Clinical and Laboratory Standards Institute; 2008.
   Google Scholar
• Harris EK, Boyd JC. On dividing reference data into subgroups to produce separate reference ranges. Clin Chem 1990;36:265–70.
   PubMed Web of Science ®Google Scholar
• Seber GAF, Wild CJ. Nonlinear regression. John Wiley & Sons. New York; 1989. ISBN 0471617601.
   Google Scholar
• Mannello F. Effects of blood collection methods on gelatin zymography of matrix metalloproteinases. Clin Chem 2003;49:339–40.
   Google Scholar
• Kodama S, Iwata K, Iwata H, Yamashita K, Hayakawa T. Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases: an application for rheumatoid arthritis in serum and plasma. J Immunol Meth 1990; 127:103–8.
   PubMed Web of Science ®Google Scholar
• Jung K, Nowak L, Lein M, Henke W, Schnorr D, Loening SA. Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in blood. Clin Chem 1996;46:2043–5.
   Google Scholar
• Lein M, Nowak L, Jung K, Koenig F, Liuchtinghagen R, Schnorr D, Loening SA. Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood. Clin Biochem 1997;30:491–6.
   PubMed Web of Science ®Google Scholar
• Jung K, Laube C, Lein M, Lichtinghagen R, Tschesche H, Schnorr D, Loening SA. Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. Clin Chem 1998;44:1060–2.
   PubMed Web of Science ®Google Scholar
• Jung K, Lein M, Laube C, Lichtinghagen R. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 2001;314:241–4.
   PubMed Web of Science ®Google Scholar
• Jung K, Lein M, Roemer A, Lichtinghagen R. Circulating gelatinase B (MMP-9): the impact of preanalytical step of blood collection. Matrix Biol 2002;21:381–2.
   PubMed Web of Science ®Google Scholar
• Alby C, Abdesselam OB, Foglietti MJ, Beaudeux JL. Preanalytical aspects regarding the measurement of metalloproteinase-9 and tissue inhibitor or metalloproteinase-1 in blood. Clin Chim Acta 2002;325:183–6.
   PubMed Web of Science ®Google Scholar
• Mannello F, Luchetti F, Canonico B, Papa S. Effect of anticoagulants and cell separation media as preanalytical determinants on zymographic analysis of plasma matrix metalloproteinases. Clin Chem 2003;49:1956–7.
   PubMed Web of Science ®Google Scholar
• John M, Jung K. Pre-analytical conditions for the assessment of circulating MMP-9 and TIMP-1: consideration of pitfalls. Eur Respir J 2005;26:364–6.
   PubMed Web of Science ®Google Scholar
• Jung K, Meisser A, Bischof P. Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes. Int J Cancer 2005;116:1000–1.
   PubMed Web of Science ®Google Scholar
• Jung K, Gerlach RF, Tanus-Santos JE. Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases. Clin Chim Acta 2006;373:180–1.
   PubMed Web of Science ®Google Scholar
• Jung K. Sample processing and its preanalytical impact on the measurement of circulating matrix metalloproteinases. Clin Chem Lab Med 2006;44:500–2.
   PubMed Web of Science ®Google Scholar
• Jung K. Impact of blood sampling on circulating tissue inhibitors of metalloproteinases. Clin Cancer Res 2006; 12:2648.
   PubMed Web of Science ®Google Scholar
• Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002;61:161–6.
   PubMed Web of Science ®Google Scholar
• Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldmann M. Reduction of serum matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumor necrosis factor-a (cA2) therapy. Br J Rheumatol 1997;36:643–50.
   PubMedGoogle Scholar
• Iizasa T, Fujisawa T, Suzuki M, Motohashi S, Yasufuku K, Yasukawa T, Baba M, Shiba M. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 1999;5:149–53.
   PubMed Web of Science ®Google Scholar
• Ekim M, Sekeroglu MR, Balahoroglu R, Ozkol H, Ekim H. Roles of the oxidative stress and ADMA in the development of deep venous thrombosis. Biochem Res Int 2014;2014: 703128.
   PubMedGoogle Scholar
• Celik M, Cerrah S, Arabul M, Akalin A. Relation of asymmetric dimethylarginine levels to macrovascular disease and inflammation markers in type 2 diabetic patients. J Diabetes Res 2014;2014:139215.
   PubMed Web of Science ®Google Scholar